

## References — Travatan

1. Travatan product monograph.
2. Fellman RL, Sullivan EK, Ratliff M, *et al.* Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure. *Ophthalmology* 2002;109:998-1008.
3. Goldberg I, Cunha-Vaz, J, Jakobsen JE, *et al.* Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. *J Glaucoma* 2001;10:414-22.
4. Gray J (ed). *Therapeutic Choices*, 3<sup>rd</sup> edition. Canadian Pharmacists Association, 2000; Ottawa.
5. Netland PA, Landry T, Sullivan EK *et al.* Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. *Am J Ophthalmol* 2001;132(4):472-84.
6. Orengo-Nania S, Landry T, Von Tres M, *et al.* Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. *Am J Ophthalmol* 2001;132:860-8.
7. Product monograph of Lumigan (bimatoprost). Allergan Inc. Markham, Ontario. May 14, 2002.
8. Product monograph of Travatan (travoprost). Alcon Canada Inc. Mississauga, Ontario. November 2001.
9. Repchinsky C, editor. *Compendium of Pharmaceuticals and Specialties*, 37<sup>th</sup> Edition. Canadian Pharmacists Association, 2002, Ottawa.
10. Vaidergorn PG, Susanna Jr R, Borges AS, Giampani Jr J. Duration of therapy provided by bottle of ocular hypotensive eyedrops (abstract). *Revista Brasileira de Oftalmologia* 2002;61(4):278-82.
11. Nicolela MT, Chauhan BC. Ocular Hypertension. In: Fraunfelder FT, Roy FH, eds. *Current Ocular Therapy*. 5<sup>th</sup> ed. W.B Saunders Company. Philadelphia, Pennsylvania. 2000. p. 491-3.